Dianthus Therapeutics (DNTH) Income from Continuing Operations (2017 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Income from Continuing Operations of 162854000.0 for Q3 2025, down 118.65% year-over-year from 873130490.5 in Q3 2024, and down 222.04% quarter-over-quarter from 50570000.0 in Q2 2025.
Dianthus Therapeutics (DNTH) Income from Continuing Operations (2017 - 2025) Analysis & Trends
Dianthus Therapeutics' Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 162854000.0 for Q3 2025.
- In Q3 2025, Income from Continuing Operations fell 118.65% year-over-year to 162854000.0; the TTM figure through Sep 2025 stood at 284944000.0 (down 30.12% YoY), while the FY2024 annual figure was 266104000.0, down 59.48% from the prior year.
- Income from Continuing Operations for Q3 2025 stood at 162854000.0, down from 50570000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 7094000.0 in Q1 2023, with the low at 162854000.0 in Q3 2025.
- The 5-year median for Income from Continuing Operations is 32856000.0 (2022), against an average of 42427421.05.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations jumped 81.67% in 2023, then tumbled 872.48% in 2024.
- Dianthus Therapeutics' Income from Continuing Operations stood at 24486000.0 in 2021, then soared by 58.94% to 10053000.0 in 2022, then declined by 4.57% to 10512000.0 in 2023, then tumbled by 167.56% to 28126000.0 in 2024, then plunged by 479.02% to 162854000.0 in 2025.
- Business Quant data shows DNTH's Income from Continuing Operations at 162854000.0 in Q3 2025, 50570000.0 in Q2 2025, and 43394000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -162.85 Mn |
| Jun 30, 2025 | -50.57 Mn |
| Mar 31, 2025 | -43.39 Mn |
| Dec 31, 2024 | -28.13 Mn |
| Sep 30, 2024 | -74.48 Mn |
| Jun 30, 2024 | -65.00 Mn |
| Mar 31, 2024 | -68.99 Mn |
| Dec 31, 2023 | -10.51 Mn |
| Sep 30, 2023 | -22.50 Mn |
| Jun 30, 2023 | -11.09 Mn |
| Mar 31, 2023 | -7.09 Mn |
| Dec 31, 2022 | -10.05 Mn |
| Sep 30, 2022 | -49.41 Mn |
| Jun 30, 2022 | -60.52 Mn |
| Mar 31, 2022 | -32.86 Mn |
| Dec 31, 2021 | -24.49 Mn |
| Sep 30, 2021 | -24.88 Mn |
| Jun 30, 2021 | -24.38 Mn |
| Mar 31, 2021 | -34.93 Mn |
| Dec 31, 2020 | -91.77 Mn |